Aviragen Therapeutics (AVIR) Misses Q4 EPS Views

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.18), $0.43 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $60 thousand versus the consensus estimate of $21 million.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'
• Atea Pharmaceuticals completes enrollment in phase 3 HCV trial